Information Provided By: 
Fly News Breaks for March 2, 2018
OPK
Mar 2, 2018 | 07:52 EDT
Cantor Fitzgerald analyst Louise Chen says that despite the Q4 miss, she reiterates an Overweight rating on Opko Health with a $20 price target. The analyst continues to think Opko's long term sales and earnings potential are underappreciated and that upward earnings revisions in 2019 and beyond should drive the stock higher. She sees the uptake of Rayaldee, commercialization of the company's branded drug pipeline, and BioReference sales growth bringing consensus estimates higher.
News For OPK From the Last 2 Days
There are no results for your query OPK
